{"id":"W4295817549","doi":"10.1016/j.annonc.2022.07.647","title":"519MO Phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab in recurrent or metastatic (R/M) cervical cancer: Long-term survival analysis","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Adenocarcinoma; Cervical cancer; Population; Clinical endpoint; Oncology; Cancer; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001414147,0.001026907,0.001695485,0.0003289572,0.0003178695,0.001101624,0.0007374564,0.0009570007,0.004332977],"category_scores_gemma":[0.0006872935,0.0003202552,0.001684438,0.0003127631,0.0006195318,0.0007048643,0.0003812812,0.00245929,0.001298438],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009991308,"about_ca_system_score_gemma":0.001032879,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001141542,"about_ca_topic_score_gemma":0.005986617,"domain_scores_codex":[0.9996026,0.0001732126,0.00001094689,0.00006211545,0.00003709214,0.0001140463],"domain_scores_gemma":[0.9996113,0.00006928926,0.00006556047,0.00004378262,0.00002370701,0.0001863662],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6227437,0.01485031,0.01329247,0.002079333,0.00507161,0.0002958404,0.0002826542,0.007806014,0.02995181,0.001538607,0.02432138,0.2777662],"study_design_scores_gemma":[0.5032537,0.3771885,0.07194881,0.0003939207,0.005225576,0.0006835557,0.0003105461,0.007362574,0.005433802,0.00206463,0.02600653,0.0001277748],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9748632,0.008553796,0.0007493715,0.001455667,0.0003209082,0.001161502,0.004804715,0.00020077,0.007890196],"genre_scores_gemma":[0.968585,0.005068049,0.0013774,0.002185971,0.000253496,0.001601805,0.008698233,0.00009056315,0.01213961],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004332977,"threshold_uncertainty_score":0.01449531,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1354505986576437,"score_gpt":0.4640827921681646,"score_spread":0.3286321935105209,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}